checkAd

     113  0 Kommentare Wellbeing Digital to Participate in the Psychedelic Medicine Association Webinar

    Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that Najla Guthrie, CEO of Wellbeing, will participate at the upcoming Psychedelic Medicine Association (PMA) Webinar on Thursday, January 26th at 5 pm Pacific, 8 pm Eastern.

    Najla will participate on “Increasing Access to Psychedelic Medicines and Therapies,” panel on January 26th at 5 pm PST/8pm EST.

    Anzeige 
    Handeln Sie Ihre Einschätzung zu NYMEX WTI Rohöl (Light Sweet Crude Oil) 12/2024 Future!
    Short
    84,00€
    Basispreis
    5,37
    Ask
    × 14,62
    Hebel
    Long
    73,00€
    Basispreis
    5,35
    Ask
    × 14,27
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    Members of the PMA can register to attend here.

    For more information about the webinar, or to schedule a one-on-one meeting with Wellbeing management team, please send an email to Natalie Dolphin at ndolphin@wellbeingdigital.co.

    ABOUT WELLBEING DIGITAL SCIENCES

    Wellbeing Digital Sciences Inc. is an evidence-based mental healthcare company focused on the development and implementation of innovative clinical treatment solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research. Its mission is supported by a network of North American clinics that provide forward-thinking therapies and other types of treatment to patients as well as through a contract research organization that offers clinical trials services to clients pursuing drug development. For additional information, please visit wellbeingdigital.co.

    On behalf of:
    Najla Guthrie
    Chief Executive Officer
    WELLBEING DIGITAL SCIENCES

    Notice Regarding Forward-Looking Information:

    This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.

    The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.




    Business Wire (engl.)
    0 Follower
    Autor folgen

    Wellbeing Digital to Participate in the Psychedelic Medicine Association Webinar Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic …